Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives

Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives

Although new inhaled antibiotics have profoundly improved respiratory diseases in cystic fibrosis (CF) patients, lung infections are still the leading cause of death. Inhaled antibiotics, i.e., colistin, tobramycin, aztreonam lysine and levofloxacin, are used as maintenance treatment for CF patients...

Full description

Bibliographic Details
Main Authors: Giovanni Taccetti, Michela Francalanci, Giovanna Pizzamiglio, Barbara Messore, Vincenzo Carnovale, Giuseppe Cimino, Marco Cipolli
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Antibiotics
Subjects:
cystic fibrosis
<i>P. aeruginosa</i>
inhaled antibiotics
pulmonary exacerbations
Online Access:https://www.mdpi.com/2079-6382/10/3/338

Internet

https://www.mdpi.com/2079-6382/10/3/338

Similar Items